In the field of immune-mediated inflammatory disease (IMID) treatment, the advent of biologic therapies has broken the limitations of traditional approaches and brought renewed hope for recovery to countless patients. As the world’s first fully human monoclonal antibody targeting interleukin-17A (IL-17A) to receive regulatory approval, secukinumab (Cosentyx) injection has...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek
